Study on ABL103 and Pembrolizumab, With or Without Taxane, for Advanced or Metastatic Solid Tumors

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of advanced or metastatic solid tumor that cannot be surgically removed.
• Cancer must have returned after treatment or not responded to standard treatments, or the patient cannot tolerate standard treatments.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Must have recovered from side effects of previous treatments to a mild level or baseline, except for hair loss or stable, irreversible side effects.
• Must have adequate blood, kidney, liver, and thyroid function based on tests.
• Women who can become pregnant must use effective birth control during the study and for six months after the last dose.
• Women must have a negative pregnancy test before starting the study.
• Men with partners who can become pregnant must use contraception and not donate sperm during treatment and for six months after the last dose.
• Men with pregnant or breastfeeding partners must use a condom or remain abstinent during the study and for six months after the last dose.

Exclusion Criteria

• Have received previous cancer treatments that have not resolved their effects before starting the study.
• Have had radiation therapy within two weeks before starting the study or have radiation-related side effects needing steroids.
• Have had previous immunotherapy stopped due to severe side effects, except for treatable hormone-related issues.
• Have had radiation to the lungs over a certain dose within six months before starting the study.
• Have risk factors for bowel problems, such as a history of certain abdominal conditions. Patients with ovarian cancer and a history of abdominal issues may still be eligible.